{"product_id":"eurofins-pestle-analysis","title":"Eurofins Scientific PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory shifts, technological advances, and global market pressures are shaping Eurofins Scientific’s strategic outlook in our concise PESTLE snapshot—then unlock the full, actionable analysis to inform investments and strategy. Purchase the complete PESTLE for a deep-dive on risks, opportunities, and sector trends ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShifts in US-China-EU trade relations affect movement of laboratory samples and equipment; in 2024 global trade tensions saw US-China tariffs and EU export screenings, raising logistics costs—Eurofins reported ~€6.5bn revenues in 2023 and faces higher cross-border service costs from increased tariffs and compliance burdens.\u003c\/p\u003e\n\u003cp\u003eExport controls on diagnostics and specialty reagents have tightened, increasing per-shipment compliance costs by an estimated 5–8% industrywide in 2023–24, pressuring Eurofins’ margins on international projects.\u003c\/p\u003e\n\u003cp\u003eTo mitigate risk, Eurofins operates a decentralized network of ~900 labs across 50+ countries (2024), reducing exposure to localized trade barriers and enabling rerouting of samples and services when borders or tariffs disrupt specific corridors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare and R\u0026amp;D Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic funding levels for healthcare and pharmaceutical R\u0026amp;D shape demand for Eurofins services; OECD countries increased health R\u0026amp;D spending to about 0.8% of GDP on average in 2024, boosting clinical testing volumes. Shifts in priorities—eg. EU pandemic preparedness grants of €10.5bn (2024–26) and rising oncology research funding—drive surges in virology and bioanalytical work for specific Eurofins divisions. Eurofins tracks national budgets and political signals to scale capacity toward regions receiving the largest public investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical moves toward regulatory harmonization—including EU-US discussions on mutual recognition and OECD initiatives—reduce barriers for Eurofins, enabling broader use of its 200,000 analytical methods across 50+ countries where it operates, potentially lowering compliance costs by an estimated 10–15% per region.\u003c\/p\u003e\n\u003cp\u003eConversely, rising protectionism or divergent national standards would force Eurofins to sustain duplicate accreditations and localized labs, increasing overhead and capital expenditures that could erode margins, particularly in markets contributing ~30% of group revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExpansion into developing regions exposes Eurofins to political risks such as expropriation and abrupt regulatory shifts; in 2024, over 20% of Eurofins revenue came from emerging markets, increasing exposure.\u003c\/p\u003e\n\u003cp\u003eThe company targets countries with stable legal frameworks and protections for foreign-owned infrastructure, favoring jurisdictions with transparent investment laws and IP enforcement.\u003c\/p\u003e\n\u003cp\u003eManagement conducts continuous political-risk assessments to safeguard laboratory assets and IP, using country-risk scores and scenario planning to protect long-term value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20%+ 2024 revenue from emerging markets\u003c\/li\u003e\n\u003cli\u003eFocus on jurisdictions with strong IP and investment protections\u003c\/li\u003e\n\u003cli\u003eOngoing country-risk monitoring and scenario planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutsourcing of Public Health Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical trends in the EU and UK show growing outsourcing of environmental and food safety monitoring to private labs, with governments cutting lab budgets by up to 15% and shifting an estimated €1.2bn in annual testing spend toward private providers by 2024.\u003c\/p\u003e\n\u003cp\u003eThis shift offers Eurofins material growth, supporting its 2024 testing revenue of €3.9bn and potential contract wins as states pursue efficiency gains and faster turnaround times.\u003c\/p\u003e\n\u003cp\u003eSustaining and expanding public contracts requires targeted political engagement, demonstrated public-health outcomes, and transparent cost-benefit reporting to secure multi-year agreements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket shift: ~€1.2bn public testing outsourced by 2024\u003c\/li\u003e\n\u003cli\u003eEurofins scale: €3.9bn testing revenue in 2024\u003c\/li\u003e\n\u003cli\u003eRisk: need for political engagement to retain contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins faces political risks and €10.5bn EU grants amid €6.5bn revenue mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—trade tensions, export controls, protectionism and public funding priorities—materially affect Eurofins’ costs and demand; c.€6.5bn group revenue (2023), €3.9bn testing revenue (2024), 20%+ from emerging markets, EU pandemic grants €10.5bn (2024–26) and ~€1.2bn public testing outsourced (2024) drive both risk and growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue (2023)\u003c\/td\u003e\n\u003ctd\u003e€6.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e€3.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets share (2024)\u003c\/td\u003e\n\u003ctd\u003e20%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU pandemic grants (2024–26)\u003c\/td\u003e\n\u003ctd\u003e€10.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic testing outsourced (2024)\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces uniquely influence Eurofins Scientific, with data-backed trends and region-specific examples to identify risks and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Eurofins Scientific PESTLE summary that’s visually segmented for quick interpretation, easily shareable for team alignment, and editable to add region- or business-specific notes for use in presentations and planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Inflation and Wage Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh demand for specialized scientists and lab technicians has driven wage inflation in biotech—global lab salaries rose about 6–8% in 2024, pressuring margins for Eurofins, which reported 2024 adjusted EBIT margin of ~12.5%. Eurofins must balance competitive pay with price-sensitive clients, using targeted compensation and benefits to retain top-tier talent. The company expanded automation, investing ~€120m in 2023–24 to cut routine labor costs and preserve profitability while maintaining analytical quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Volatility in Global Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Eurofins operates in over 50 countries, 2024 FX swings—notably a ~9% euro weakness vs. USD in 2023–24—can materially affect reported revenue (€7.9bn FY2023) and EUR-denominated debt servicing; management uses hedging (forward contracts covering a significant portion of forecasted FX exposure) and geographic diversification to limit single-currency risk. Financial planners must model currency scenarios when consolidating global earnings and timing €200–300m annual capex for lab upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Allocation and Interest Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher mid-2020s interest rates raised Eurofins’ weighted average cost of debt, pressuring its historically acquisition-led growth; the group’s net debt\/EBITDA fell to about 2.1x in FY2024 from ~2.6x in 2022 as management tightened deal discipline.\u003c\/p\u003e\n\u003cp\u003eWith Euribor and US rates averaging ~3.5–4.5% in 2024–25, the firm targets high-margin niche targets and prioritizes free cash flow—operating cash flow of €1.2bn in 2024—to fund capex and reduce reliance on costly external financing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical R\u0026amp;D Spending Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe economic health of pharma\/biotech drives outsourcing for drug discovery and trials; global pharma R\u0026amp;D hit about $238bn in 2024, sustaining demand for contract testing despite biotech funding dips.\u003c\/p\u003e\n\u003cp\u003eTight capital markets force smaller biotechs to cut R\u0026amp;D—venture funding for biotech fell ~28% in 2023–2024—reducing specialized testing volume.\u003c\/p\u003e\n\u003cp\u003eEurofins offsets this with diversified clients: top 10 pharma account for a stable share, and large pharma R\u0026amp;D remained resilient, keeping utilization steady.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 global pharma R\u0026amp;D: ~$238bn\u003c\/li\u003e\n\u003cli\u003eBiotech venture funding drop ~28% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eDiversified client base reduces revenue volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-of-Living Impact on Consumer Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns reduce spending on premium foods and cosmetics, cutting discretionary testing volumes; e.g., global luxury goods sales fell 10% in 2023, pressuring manufacturers to cut testing budgets.\u003c\/p\u003e\n\u003cp\u003eMandatory safety testing remains steady—Eurofins reported resilient core testing demand in 2024 with organic revenue growth of ~6% across regulated services.\u003c\/p\u003e\n\u003cp\u003ePortfolio diversification into environmental and pharma testing buffers cyclicality; environmental testing grew ~8% in 2024, offsetting weaker consumer-related volumes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiscretionary testing tied to luxury\/food declines with luxury sales -10% (2023)\u003c\/li\u003e\n\u003cli\u003eMandatory safety testing stable; Eurofins organic revenue growth ~6% (2024)\u003c\/li\u003e\n\u003cli\u003eEnvironmental testing +8% (2024) provides cyclicality buffer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWage-driven margin squeeze, €7.9bn revenue \u0026amp; €120m capex as pharma R\u0026amp;D sustains demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWage inflation (lab pay +6–8% in 2024) and €120m automation capex pressured margins (2024 adj. EBIT ~12.5%); FX volatility (euro -9% vs USD in 2023–24) affects €7.9bn revenue; net debt\/EBITDA ~2.1x (2024) after tighter M\u0026amp;A; pharma R\u0026amp;D ~$238bn (2024) sustains demand while biotech VC fell ~28% (2023–24), environmental testing +8% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€7.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBIT margin\u003c\/td\u003e\n\u003ctd\u003e~12.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~2.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab wage inflation\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$238bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEurofins Scientific PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Eurofins Scientific PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use without placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752085959033,"sku":"eurofins-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eurofins-pestle-analysis.png?v=1772237310","url":"https:\/\/matrixbcg.com\/products\/eurofins-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}